Skip to content
Kalpvruksh Markets
Offline Log in

GLENMARKNSEOffline

GLENMARK PHARMA · INE935A01035 · Mid Cap · #177
2,481.80−22.90 (−0.91%)last close · 05 Nov 2026
Prev close
2,504.70
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹60,826 cr
52-week range · to 05 Nov 20261,810.42,515

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

GLENMARK is 1% below its 52-week high, above its 200-day average, ahead of Healthcare by 8.9 pts over 3 months — a Mid Cap company, #177 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50 / 200-day averages · 1% below its 52-week high
  • ahead of its industry by 8.9 pts over 3 months · rank 14 of 44 in Healthcare · +12.3% vs Nifty 500
  • traded value 1.9× usual · delivery 47% vs 49% usual
  • long unwinding today · IV 34%, 82nd pct of its year · expected move ±7.4% to expiry
  • FPI +0.6 pp · DII −1.0 pp · MF schemes in Sept 2026: 68 bought, 78 cut · no promoter pledge · quarter ended 2026-09-30
  • Jun 2026 quarter: profit +930% year on year · revenue +23%
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹60,826 cr
Rank
#177
Cap band
Mid Cap
Nearest cut-off — Large / Mid
−42.84% from ₹1,06,417 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.4×
median 2,72,102
Delivered
3,77,139
Of volume
41%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+6.1%+0.2 pts—
1 month+7.4%+2.7 pts+3.3 pts
3 months+9.9%+12.3 pts+8.9 pts
6 months+4.4%+4.0 pts−5.9 pts
1 year+31.8%+35.3 pts—

Industry: Healthcare (Nifty 500 classification) · rank 14 of 44 over 3 months. Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+8.5%
above
vs 50-day average
+5.0%
above
vs 200-day average
+11.2%
above
ATR (14)
3.3%
typical daily range
Volatility
34%
1 month, annualised
Beta
0.99
vs Nifty 500, 1 year
Traded value
1.9×
vs usual
Delivery
47%
usual 49%
From the 52-week high
−1.3%
place in range 95% (0 = at the low)

F&O

Where option open interest clusters

expiry 23 Nov 2026 · 18 days

Spot
2,481.8
Max pain
2,360
−4.9% from spot
Largest call OI (strike)
Largest put OI (strike)

Near expiry. Max pain is the strike at which option buyers’ total payout would be least; strikes with the most open interest are where positions cluster.

Volatility & expected move

ATM IV
33.5%
near expiry
IV 30
33.7%
IV rank
66
0–100 within its year
IV percentile
82
days in the year below today
Expected move to expiry
±184.58
±7.4% · one standard deviation
Range
2,297 – 2,666
Rollover
0%
futures OI in next expiries

Futures build-up, by day

all expiries' OI · today: long unwinding

SessionBuild-upFuture priceOI, all expiries
05 Nov 2026long unwinding−1.5%−2.2%
04 Nov 2026long build-up+4.6%+2.7%
03 Nov 2026long build-up+1.0%+1.2%
02 Nov 2026short covering+2.7%−1.0%
30 Oct 2026long unwinding−0.7%−0.1%
29 Oct 2026long build-up+1.6%+0.6%
28 Oct 2026short covering+1.0%−1.1%
27 Oct 2026long build-up+2.2%+0.6%
26 Oct 2026short covering+4.2%−0.4%
23 Oct 2026long unwinding−2.7%−2.5%

From the exchanges’ F&O bhavcopies. A description of positions, not a forecast. Open interest across the market.

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters46.6%46.6%46.6%46.6%
FPI19.2%20.4% +1.220.9% +0.521.5% +0.6
Mutual funds17.9%16.8% −1.116.8%15.6% −1.2
Other DII2.2%2.5% +0.21.8% −0.62.0% +0.2
Individuals10.8%10.3% −0.410.6% +0.310.4% −0.2
Others3.3%3.4% +0.13.3% −0.13.8% +0.5

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
2,08,414
Individuals
1,96,223

Indian passive funds’ stake

2026-06-30

Of free float
1.91%
Of all shares
1.02%
Schemes
105
Days to unwind
4.2
at 100% of volume

28,74,109 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
227
105 index · 122 active
Bought more
130
Sold some
61
FundSharesChangeDid
Invesco India Arbitrage Fund-Reg(G)Active+8,62,125+279.0%bought
Baroda BNP Paribas ELSS Tax Saver Fund-Reg(G)Active+31,992+177.7%bought
Baroda BNP Paribas Health and Wellness Fund-Reg(G)Active+50,000+166.7%bought
Aditya Birla SL Balanced Advantage Fund(G)Active−40,400−85.7%sold
Mahindra Manulife Multi Cap Fund-Reg(G)Active−6,17,003−62.4%sold
Bandhan Multi Asset Allocation Fund-Reg(G)Active−40,000−53.3%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 2618013556612+2.4%₹8,780 cr
Aug 2617918734814−3.9%₹9,099 cr
Jul 261741055546+0.2%₹8,526 cr
Jun 26170592358+0.3%₹8,399 cr
May 261731375372+2.0%₹8,638 cr
Apr 26162689344−1.3%₹8,960 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Credit rating
    Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating
    11 Sept 2026
  • Board outcome
    Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    03 Aug 2026
  • Board outcome
    Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
    01 Jun 2026

GLENMARK: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
RecentDividend₹2.5Final31 Aug 202631 Aug 2026
EarlierDividend₹2.5Interim03 Oct 202503 Oct 2025
EarlierDividend₹2.5Final15 Sept 202515 Sept 2025
EarlierDividend₹2.5Final13 Sept 202417 Sept 2024
EarlierDividend₹2.5Final18 Sept 202319 Sept 2023
EarlierDividend₹2.5Final12 Sept 202214 Sept 2022
EarlierDividend₹2.5Final08 Sept 202110 Sept 2021
EarlierBonus1:1—04 Mar 200508 Mar 2005

8 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.